Product Description
Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired resistance mechanisms. In vitro, eravacycline exhibits potent activity against a broad spectrum of clinically relevant Gram-positive and -negative aerobic and anaerobic bacteria. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505493/)
Mechanisms of Action: 30S Ribosomal Subunit Antagonist,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hong Kong | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | Poland | Portugal | Romania | Singapore | Slovakia | Slovenia | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Communicable Diseases|Intraabdominal Infections|Urinary Tract Infections|Appendicitis
Phase 2: Community-Acquired Infections|Communicable Diseases|Intraabdominal Infections|Neutropenia
Phase 1: Healthy Volunteers|Other|Kidney Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05537896 | P2 |
Recruiting |
Neutropenia |
2028-02-01 |
|
| ChiCTR2300078646 | N/A |
Recruiting |
Unknown |
2026-12-31 |
|
| LPan20230578 | N/A |
Not yet recruiting |
Other |
2025-12-31 |
|
| ChiCTR2400087137 | N/A |
Not yet recruiting |
Pneumonia, Ventilator-Associated |
2025-12-31 |